CHIRON |
Science
For Life
TRAFFIC
Phase II, multi-center, randomized, double-blind,
placebo-controlled, regimen finding study comparing placebo, one, or two doses
of
rFGF-2
Investigators:
PARC (www.arterial.org)
PI:
Brian
Annex & Robert Lederman
Sponsor:
Chiron
Corporation
CC: DCRI